After how long of discontinuation of a GLP‑1 receptor agonist (e.g., semaglutide, dulaglutide, liraglutide, exenatide) should the patient restart at the original starting dose rather than the previous dose?

GLP-1 Receptor Agonist Restart Dosing After Discontinuation

If a patient has missed 3 or more consecutive doses of a GLP-1 receptor agonist, restart at the initial titration dose rather than the previous maintenance dose. 1

Dosing Algorithm Based on Duration of Discontinuation

For Weekly GLP-1 RAs (Semaglutide, Dulaglutide):

• ≤2 consecutive doses missed (≤2 weeks): Resume at the same dose if previously well-tolerated 1
• 3+ consecutive doses missed (≥3 weeks): Restart the full titration schedule from the beginning 1

For Daily GLP-1 RAs (Liraglutide):

• ≤2 consecutive days missed: Resume at the same dose if previously well-tolerated 1
• 3+ consecutive days missed: Consider restarting titration schedule 1

Specific Titration Schedules When Restarting

Semaglutide (weekly):

• Start 0.25 mg weekly × 4 weeks
• Then 0.5 mg weekly × 4 weeks
• Then 1.0 mg weekly × 4 weeks
• Then 1.7 mg weekly × 4 weeks
• Target 2.4 mg weekly (reached at 16 weeks) 1

Liraglutide (daily):

• Start 0.6 mg daily × 7 days
• Then 1.2 mg daily × 7 days
• Then 1.8 mg daily × 7 days
• Then 2.4 mg daily × 7 days
• Target 3.0 mg daily (reached at 4 weeks) 1

Dulaglutide (weekly):

• Start 0.75 mg weekly
• Titrate to 1.5 mg or maximally tolerated dose 2

Clinical Judgment Factors

The 2022 AGA guideline emphasizes that clinical judgment is required when deciding subsequent dosing after missed doses 1. Consider these factors:

• Previous tolerability: If the patient tolerated the medication exceptionally well without GI side effects, resuming at the same dose may be reasonable for shorter lapses (≤2 doses) 1
• Duration of therapy lapse: The longer the gap, the more important it is to restart titration 3
• Prior GI symptoms: If the patient had significant nausea/vomiting previously, err toward restarting at lower doses 1

Critical Safety Rationale

The primary reason for restarting at lower doses is to minimize GI adverse effects, particularly nausea and vomiting 1. A case report documented severe, symptomatic nausea and vomiting requiring medical intervention when a patient restarted semaglutide at target dose after a 7-week lapse, rather than restarting titration 3.

GLP-1 RAs cause dose-dependent GI side effects in 40-51% of patients (nausea) and 16% (vomiting) 1. Gradual dose titration is the primary strategy to minimize these effects 1.

Common Pitfalls to Avoid

• Do not assume tachyphylaxis persists after prolonged discontinuation: While some tolerance to GI effects develops with chronic use, this likely dissipates after extended therapy gaps
• Insurance interruptions are common: Proactively counsel patients about the need to restart titration if access is delayed ≥3 weeks 3
• Document the restart plan clearly: Specify whether resuming at same dose or restarting titration to avoid confusion at the pharmacy level